Remove 2014 Remove Doctors Remove Healthcare Remove Healthcare Provider
article thumbnail

Top 12 Healthcare Technology Start-ups To Know

Medico Reach

The healthcare sector has seen a few developments over the years. Tempus began with the goal of incorporating artificial intelligence and data science into the healthcare industry. As a matter of fact, Kyruus now connects around 300,000 medical providers with over 90 million members across the US. Wondering what that is?

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. Biogen’s activity in multiple sclerosis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Liron Fendell

Cadensee

Until back in 2014, I met the team at Schneider Children's Medical Center of Israel. And I was lucky enough the team at Schneider's and Clalit Healthcare , who is the owner of Schneider Hospital. They want it to be backed by doctors. That it is was developed by doctors and backed by doctors.

Retail 52
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero. PNAS 2022, Vol.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. This class-action litigation specifically focused on a 2011 licensing agreement between the two companies. These actions allegedly led to the extension of Novartis’ patents.